CPHI & P-MEC China 2020 adapts to customer needs with hybrid pharma event

Virtual Expo Connect to empower access for international pharma to the world’s largest pharma ingredients market
CPHI & P-MEC China returns as a hybrid event in Shanghai (16-18 December, 2020), with a physical exhibition running alongside Virtual Expo Connect (18 November – 18 December, 2020) for international audiences unable to attend.
The physical exhibition will be held at the SNIEC (Shanghai New International Expo Center), with some 3,000 exhibitors present across three days, alongside exhibitor talks and conferences. Crucially, this year’s exhibition will support international attendees with a dedicated month-long digital platform, Virtual Expo Connect.
Reacting to customer needs, CPHI & P-MEC China introduced a new hybrid model so that pharma executives (unable to visit Shanghai) can continue to meet and do business in the country – which plays such an integral role in global supply chains. In fact, China is the world’s biggest ingredients producer, supplying 80% of chemicals used in European drug manufacturing and 70% of APIs to Indian manufactures - which in turn makes 40% of global generics[i].
“China based companies are absolutely vital in the pharma supply chain. It is therefore essential international pharma is able to meet with partners here to support the delivery of medicines globally. For international attendees to connect with China-based suppliers, we created a special digital platform. Virtual Expo Connect provides access to thousands of potential suppliers over a one-month long period of engagement, allowing pharma to source connections to support manufacturing needs. To sustain global growth, it is crucial that overseas professionals can meet with companies from the world’s largest pharma ingredients market,” commented Laura Murina – Brand Manager CPHI & P-MEC China, Informa Markets
The onsite and digital exhibitors will span the full supply chain in China – from ingredients and machinery to contract services, biologics, finished dosage and packaging.
Virtual Expo Connect will have a number of digital features at the disposal of online attendees. For example, the Digital Showroom will showcase products and services from the event’s exhibitors, with attendees able to search for suppliers and request video meetings. Business development will be further facilitated by the online matchmaking service, which uses precise targeting to source the most appropriate partners. The virtual expo also provides hosted buyer video meetings, a customised one-to-one digital meeting service tailored to individual purchasing requirements.
Additionally, to stay informed on the latest challenges and opportunities, the exhibitor talks will feature in-depth interviews with senior management from across leading pharmaceutical companies in China. Further industry expert insights will also be provided by the conference webcasts, which are available to livestream and on-demand.
Finally, for a fully immersive experience of CPHI & P-MEC China, virtual attendees will have the chance to tour the show floor via both a 360o virtual reality view of the show floor and livestreamed virtual guided tours.
Murina added “Following the success of the recent CPHI: Festival of Pharma, we realised the importance for international audiences of combining the benefits of Virtual Expo Connect. Yet with our 360o virtual reality and guided tours we have taken this a step further and we now empower the global community with a truly immersive digital event experience. The online and on-demand conference agenda will deliver vital information on market dynamics, opportunities and trends. All from the comfort of executives own computers and over an extended month-long period.”
International attendees can register for CPHI & P-MEC China 2020 Virtual Expo Connect here. CPHI believes that quality of life can be improved through attainable healthcare, delivered by more accessible and affordable medicines – which it empowers through providing professionals’ platforms to meet and exchange ideas.

Related News
-
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News China import tax fine could cost AstraZeneca up to US$8 million
British-Swedish drugmaker AstraZeneca could find itself facing fines of up to US$8million in China due to suspected unpaid import taxes on breast cancer drug Enhertu.
-
News Pharmaceutical Packaging Market Prospects – Innovations in Packaging and Drug Delivery
Download the Pharmaceutical Packaging Market Prospects Trend Report to explore the full report and delve into the evolving opportunities in pharmaceutical packaging and drug delivery. -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News WuXi to sell CGT manufacturing unit to US-based Altaris LLC
At the tail end of 2024, Chinese-based CDMO WuXi AppTec announced the signing of their deal with private equity firm Altaris LLC, confirming the sale of WuXi Advanced Therapies, the cell and gene therapy manufacturing arm of WuXi AppTec. -
News BIOSECURE Act not included in key defense spending bill for 2025
On December 7, 2024, the Biden administration revealed the 2025 National Defense Authorization Act, an annual defense bill specifying the budget and expenditures of the US Department of Defense. The controversial BIOSECURE Act was notably missing from ... -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden...